Skip to content
Ivermectin
Sklice, Soolantra, Stromectol (ivermectin) is an unknown pharmaceutical. Ivermectin was first approved as Stromectol on 1996-11-22. It is used to treat ascariasis, elephantiasis, enterobiasis, lice infestations, and mansonelliasis amongst others in the USA. It is known to target P2X purinoceptor 4, neuronal acetylcholine receptor subunit alpha-7, and P2X purinoceptor 7.
Download report
Favorite
COVID-19
Case Study: COVID-19
Searched
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Sklice, Soolantra, Stromectol (generic drugs available since 2014-10-24)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ivermectin
Tradename
Company
Number
Date
Products
SKLICEArbor PharmaceuticalsN-202736 OTC2012-02-07
1 products, RLD, RS
SOOLANTRAGaldermaN-206255 RX2014-12-19
1 products, RLD, RS
STROMECTOLMerck Sharp & DohmeN-050742 RX1998-10-08
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ivermectinANDA2023-06-07
skliceNew Drug Application2021-05-13
soolantraNew Drug Application2019-11-26
stromectolNew Drug Application2020-11-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ascariasisEFO_0007154D001196B77
elephantiasisEFO_0004711D004604
enterobiasisD017229B80
lice infestationsD010373B85.2
mansonelliasisEFO_0007357D008368B74.4
onchocerciasisEFO_0007402D009855B73
scabiesD012532B86
strongyloidiasisEFO_0007501D013322B78
trichuriasisEFO_0007524D014257B79
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Ivermectin, Soolantra, Galderma Labs Lp
90895872034-03-13U-1631
92331172034-03-13U-1631
92331182034-03-13U-1631
97824252034-03-13U-1631
102069392034-03-13U-1631
75504402024-04-22DPU-1631
80805302024-04-22DPU-1631
80932192024-04-22DPU-1631
84153112024-04-22DPU-1631
84707882024-04-22DPU-1631
88158162024-04-22DPU-1631
110335652024-04-22DP
ATC Codes
D: Dermatologicals
D11: Other dermatological preparations in atc
D11A: Other dermatological preparations in atc
D11AX: Other dermatological preparations in atc
D11AX22: Ivermectin
P: Antiparasitic products, insecticides and repellents
P02: Anthelmintics
P02C: Antinematodal agents
P02CF: Avermectines
P02CF01: Ivermectin
HCPCS
No data
Clinical
Clinical Trials
192 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.18322871473
Filarial elephantiasisD004605EFO_0007272B74.0444516
ScabiesD012532B861252313
RosaceaD012393L71226211
OnchocerciasisD009855EFO_0007402B73341311
MalariaD008288EFO_0001068B5423519
Healthy volunteers/patients6117
PneumoniaD011014EFO_0003106J1823115
TrachomaD014141A71123
YawsD015001EFO_0007548A661113
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronavirus infectionsD018352EFO_0007224B34.225118
PediculusD0103741157
StrongyloidiasisD013322EFO_0007501B78516
InfectionsD007239EFO_00005443416
TrichuriasisD014257EFO_0007524B793315
Lice infestationsD010373B85.21124
AscariasisD001196EFO_0007154B771213
Hookworm infectionsD006725EFO_0007314B761213
DengueD003715A90111
Falciparum malariaD016778EFO_0007444B5011
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Severe acute respiratory syndrome-related coronavirusD045473NCBITaxon_227859223
HelminthiasisD006373EFO_1001342B65-B83123
Respiratory distress syndromeD012128EFO_1000637J80112
Severe acute respiratory syndromeD045169EFO_0000694J12.81222
PoisoningD011041EFO_0008546T65.911112
Atopic dermatitisD003876EFO_0000274L2022
NeoplasmsD009369C8011
Wounds and injuriesD014947T14.811
Ocular onchocerciasisD015827EFO_0007398B7311
Severe dengueD019595A9111
Show 5 more
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parasitic diseasesD010272EFO_0001067B8833
Bacterial infectionsD001424A4911
Drug-related side effects and adverse reactionsD064420T88.711
Hiv infectionsD015658EFO_0000764B2011
PruritusD011537HP_0000989L2911
Abdominal painD015746R10.911
LymphedemaD008209Q82.011
MansonelliasisD008368EFO_0007357B74.411
Respiratory tract infectionsD012141J06.911
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIVERMECTIN
INNivermectin
Description
Ivermectin is an antiparasitic drug. After its discovery in 1975, its first uses were in veterinary medicine to prevent and treat heartworm and acariasis. Approved for human use in 1987, today it is used to treat infestations including head lice, scabies, river blindness (onchocerciasis), strongyloidiasis, trichuriasis, ascariasis and lymphatic filariasis. It works through many mechanisms to kill the targeted parasites, and can be taken by mouth, or applied to the skin for external infestations. It belongs to the avermectin family of medications.
Classification
Small molecule
Drug classantiparasitics (ivermectin type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O
Identifiers
PDB
CAS-ID70288-86-7
RxCUI6069
ChEMBL IDCHEMBL1200633
ChEBI ID
PubChem CID9812710
DrugBankDB00602
UNII ID8883YP2R6D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
P2RX4
P2RX4
CHRNA7
CHRNA7
P2RX7
P2RX7
Organism
Homo sapiens
Gene name
P2RX4
Gene synonyms
NCBI Gene ID
Protein name
P2X purinoceptor 4
Protein synonyms
ATP receptor, ATP-gated cation channel protein, P2X receptor, subunit 4, Purinergic receptor, purinergic receptor P2X, ligand gated ion channel, 4, purinergic receptor P2X4, purinoceptor P2X4
Uniprot ID
Mouse ortholog
P2rx4 (18438)
P2X purinoceptor 4 (Q9JJX6)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 15,389 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
53,235 adverse events reported
View more details